Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinazoline SCHEMBL29144630 | 0.98 | EGFR (0.71) | EGFRPIK3CDPIK3CACHRNB2CHRNA4 | |
| Quinazoline SCHEMBL27875528 | 0.95 | EGFR (0.77) | EGFRPIK3CDPIK3CACHRNB2CHRNA4 | |
| Quinazoline SCHEMBL3686138 | 0.91 | EGFR (0.77) | EGFRPIK3CDPIK3CACHRNB2CHRNA4 | |
| Quinazoline SCHEMBL16444698 | 0.91 | EGFR (0.77) | EGFRPIK3CDPIK3CACHRNB2CHRNA4 | |
| Quinazoline SCHEMBL28041229 | 0.85 | EGFR (0.62) | EGFRPIK3CDPIK3CACHRNB2CHRNA4 | |
| Quinazoline SCHEMBL3718090 | 0.83 | EGFR (0.65) | EGFRPIK3CDPIK3CACHRNB2CHRNA4 | |
| Quinazoline SCHEMBL29490398 | 0.83 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2CYP1A2 | |
| Quinazoline SCHEMBL22833783 | 0.83 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2CYP1A2 | |
| Quinazoline SCHEMBL29356169 | 0.83 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2CYP1A2 | |
| Quinazoline SCHEMBL5920 | 0.83 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260153-A | 6-substituted chiral pure difluoropiperidine quinazoline derivative and preparation method thereof | 威尚（上海）生物医药有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220227717-A1 | ALLOSTERIC ACTIVATORS OF THE ALPHA1A-ADRENERGIC RECEPTOR | THE CLEVELAND CLINIC FOUNDATION | 2022-07-21 | — | — | US | disclosed |
| WO-2020219720-A1 | ALLOSTERIC ACTIVATORS OF THE ALPHA1A -ADRENERGIC RECEPTOR | THE CLEVELAND CLINIC FOUNDATION (US) | 2020-10-29 | — | — | WO | disclosed |
| CN-102516232-A | ErbB2 micro-molecular selective inhibitor and application thereof | WUXI MCHEM PHARMATECH CO LTD | 2012-06-27 | — | — | CN | disclosed |
| EP-0892790-B1 | NEW QUINAZOLINE-4-AMINO-2-(PIPERIDINE-1-YL-4-SUBSTITUTED) DERIVATIVES HAVING ANTI-HYPERTENSIVE ACTIVITY, A METHOD FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ROTTA RESEARCH LAB (IT) | 2004-04-14 | — | — | EP | disclosed |
| CN-1268138-A | Compounds | ASTRA PHARMA PROD (GB) | 2000-09-27 | — | — | CN | disclosed |
| US-5985885-A | USEFUL IN THE TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, PROSTATE HYPERTROPHY, VARIOUS URINARY TRACT DISORDERS AND PATHOLOGICAL SYMPTOMS CAUSED BY HYPERACTIVITY OR DISFUNCTIONING OF THE NORADRENERGIC NEURAL SYSTEM | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1999-11-16 | — | — | US | disclosed |
| EP-0892790-A1 | NEW QUINAZOLINE-4-AMINO-2-(PIPERIDINE-1-YL-4-SUBSTITUTED) DERIVATIVES HAVING ANTI-HYPERTENSIVE ACTIVITY, A METHOD FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997037979-A1 | NEW QUINAZOLINE-4-AMINO-2-(PIPERIDINE-1-YL-4-SUBSTITUTED) DERIVATIVES HAVING ANTI-HYPERTENSIVE ACTIVITY, A METHOD FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227717-A1 | ALLOSTERIC ACTIVATORS OF THE ALPHA1A-ADRENERGIC RECEPTOR | ADRA1A, ADRB1, ADRA1D | EGFR 2372/4885PIK3CD 2060/4885PIK3CA 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.